MINIMAL CHANGE DISEASE AS RARE RENAL MANIFESTATION OF PSORIASIS IN A YOUNG ADULT: A CASE REPORT
Abstract
Minimal Change Disease (MCD) is the main cause of primary nephrotic syndrome in about 90% of children, but it's very rare in adults, where it accounts for only 10% to 15% of cases. MCD is marked by symptoms like excessive protein in the urine, low levels of albumin in the blood, swelling, and high cholesterol [1,2]. It can be primary, meaning it starts on its own without a known cause, or it can be secondary, meaning it's caused by other conditions like certain medications such as Non-steroidal Anti-inflammatory Drugs (NSAIDs), cancers, infections, or other diseases affecting the kidneys or the body. These secondary causes make up up to 15% of MCD cases in adults [1]. Therefore, it's important to take a detailed medical history when diagnosing MCD in adults because treatment depends on finding the underlying cause.
How to Cite
References
- 1. Nicholas PD, Garrahy I. Adult minimal change disease with acute kidney injury: a case report and literature review. J Community Hosp Intern Med Perspect. 2019;9(6):507–10.
- 2. Saleem MA, Kobayashi Y. Cell biology and genetics of minimal change disease. F1000Res. 2016;5:F1000.
- 3. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–912.
- 4. Zadrazil J, Tichy T, Horak P, et al. IgA nephropathy associated with psoriasis vulgaris: A contribution to the entity of "psoriatic nephropathy". J Nephrol. 2006;19(3):382–6.
- 5. Debnath P, Okoye CC, Zia A, Chaudhury SR, Frolova E. Minimal Change Disease as a Sequela of Psoriasis in an Adult [Abstract]. J Am Soc Nephrol. 2021;32(10S):522.
- 6. Lok KH, Hung HG, Yip WM, Li KK, Li KF, Szeto ML. Fulminant ulcerative colitis associated with steroid-resistant minimal change disease and psoriasis: A case report. World J Gastroenterol. 2007;13(28):3889–91.
- 7. Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27(2):115–23.
- 8. Al-Oudah GA. Psoriatic-nephropathy; an under-noticed disease. J Nephropharmacol. 2025;14:e12752.
- 9. Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. Renal dysfunction in psoriatic patients. G Ital Nefrol. 2020;37(5):2020-vol1.
- 10. Ren F, Zhan X, Martens G, Lee J, Center D, Adamson A, et al. Psoriasis-like inflammation induced renal dysfunction through the TLR/NF-κB signal pathway. Biomed Res Int. 2020;2020:3535264.
- 11. Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G. Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol. 2015;54(4):478–81.
- 12. Akoglu H, Dede F, Akoglu G, Gonul II, Odabas AR. Membranoproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail. 2009;31:858–61.
- 13. Qi C, Chen L, Shen P, Li X, Pan X, Xu J, Xie J. Renal biopsy findings in psoriasis patients with renal involvement: a descriptive clinicopathologic study. BMC Nephrol. 2026;27:114.
- 14. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2003;18(2):245–8.
- 15. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332–45.
- 16. KDIGO Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–276.
- 17. Waldman M, Crew RJ, Valeri A, Appel J, Sterman L, Chois MH, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.
- 18. Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant. 2003;18(suppl 6):vi52–8.
- 19. Ranganathan S. Pathology of podocytopathies causing nephrotic syndrome in children. Front Pediatr. 2016;4:32.
- 20. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities. J Am Acad Dermatol. 2019;81(2):557–77.
- 21. Nast A, Gisondi P, Ormerod AD, Spuls PI, Augustin M, de Jong EM, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.
- 22. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273–9.
- 23. Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, et al. A novel immune-endocrine axis in idiopathic nephrotic syndrome? Pediatric Nephrology. 2005;20(11):1538–44.
- 24. Shimoyama H, Nakajima M, Naka H, Maruhashi Y, Akazawa H, Ueda T, et al. Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2004;19(10):1115–21.
- 25. Van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci. 2004;107(2):125–36.
- 26. Shimoyama H. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80(3 Pt 2):S40–5.